Medically reviewed by 
Overview
Ozempic has become shorthand for an entire class of medicines. It dominates headlines, social media and search results, so it's no surprise that many people researching weight-loss treatment in Ireland begin by searching for it. But that fame has created one of the most persistent misunderstandings in modern medicine, and it's worth stating plainly at the outset: Ozempic is licensed for type 2 diabetes, not weight loss, and we do not prescribe it.
What most people searching for "Ozempic for weight loss" actually want is the medicine inside Ozempic, semaglutide, used at the doses and in the products that are licensed for weight management. Those products are the Wegovy injection and, since 2026, the once-daily Wegovy pill. This guide explains the entire semaglutide family, the real differences between the products, why the licensing distinction matters clinically and ethically, and what an Irish-registered doctor can legitimately prescribe for weight management today.
This article is educational and is not medical advice. If you have diabetes, your treatment belongs with your GP or diabetes team, and nothing here applies to you.
The semaglutide family, explained
One molecule, three brands, three licences. Semaglutide is a GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a gut hormone that regulates appetite and blood sugar. The manufacturer, Novo Nordisk, has brought it to market in three distinct products:
Ozempic is a once-weekly injection licensed for type 2 diabetes, at maintenance doses up to 2 mg weekly. Its job is glycaemic control, reducing HbA1c and cardiovascular risk in people with diabetes. Weight loss occurs, but as a secondary effect at diabetes doses. Details of its EU licence are on the European Medicines Agency's Ozempic page.
Rybelsus is a once-daily tablet, also licensed for type 2 diabetes, at doses up to 14 mg. It was the first oral semaglutide, proof the absorption problem could be solved, but its licence and dosing belong to diabetes care. See the EMA's Rybelsus page.
Wegovy is licensed specifically for weight management in adults meeting BMI criteria. It exists as the established once-weekly injection (up to 2.4 mg) and now the once-daily tablet, the Wegovy pill, at doses up to 25 mg. The EMA's Wegovy page records the 2026 extension adding the tablet forms.
So when someone says "I want Ozempic to lose weight", the accurate translation is: "I want semaglutide for weight management", and the licensed way to have that in Ireland is Wegovy, as injection or tablet.
Why the licence distinction actually matters
It's tempting to see licensing as paperwork, same molecule, who cares which box it comes in? Three reasons, each with real-world consequences.
Dosing and evidence. Medicines are licensed for an indication based on trials at specific doses in specific populations. Wegovy's weight-management licence rests on the STEP programme (injection) and OASIS programme (tablet), which tested weight-loss outcomes in people with obesity or overweight, including the OASIS trials showing 16.6% average weight loss with the 25 mg tablet among adherent participants. Ozempic's trials measured diabetes outcomes. Prescribing within the licence means prescribing where the evidence is.
Supply ethics. Ireland, like most of Europe, experienced sustained Ozempic supply pressure as off-label weight-loss demand collided with the needs of people with diabetes who depend on it. Ireland's medicines regulator, the HPRA, and prescriber bodies repeatedly urged that Ozempic be reserved for its licensed diabetes use. Prescribing Wegovy for weight management keeps the two supply chains separate, patients with diabetes keep their medicine, and weight-management patients get a product actually licensed for them.
Clinical follow-up. A weight-management licence comes with weight-management titration schedules, monitoring expectations and stopping rules. That structured care, not just the molecule, is what produces the trial-level outcomes.
Wegovy pill vs Ozempic: the practical differences
Indication. Wegovy pill: weight management in adults with BMI ≥30, or ≥27 with a weight-related condition. Ozempic: type 2 diabetes.
Form and routine. The Wegovy pill is a once-daily tablet taken on an empty stomach with a small sip of water, followed by a 30-minute wait before food or other medicines. Ozempic is a once-weekly injection with no food rules.
Dose. The tablet's 25 mg dose versus Ozempic's 2 mg weekly looks dramatic but is meaningless as a comparison: oral semaglutide is absorbed far less efficiently than injected semaglutide, so the milligram numbers aren't equivalent. Each dose is right for its route and purpose.
Weight-loss evidence. The 25 mg Wegovy tablet produced roughly 16.6% average weight loss over 64 weeks in adherent trial participants, comparable territory to the 2.4 mg Wegovy injection (around 15% in the STEP trials). Ozempic at diabetes doses typically produces materially less weight change; it was never designed or dosed as a weight-loss product.
Availability in Ireland. The Wegovy pill is accessible to Irish patients now via our Northern Ireland dispensing route, Ozempic is available in Irish pharmacies, for people with type 2 diabetes, prescribed within its licence.
"But my friend got Ozempic for weight loss…"
Off-label prescribing, using a licensed medicine outside its licensed indication, is lawful and sometimes clinically appropriate, at an individual doctor's judgement and responsibility. During the years before Wegovy was available in Ireland, some off-label semaglutide use for weight management happened. But the clinical logic for it has now largely disappeared: products licensed and dosed for weight management exist, in both injectable and oral forms. Where a licensed option exists, prescribing it is better medicine, the evidence, the titration schedule and the safety information all match the patient in front of the doctor. That is our policy without exception: we prescribe for weight management only medicines licensed for weight management, and we do not prescribe Ozempic.
Risks and side effects: mostly shared, one key difference
Because the active ingredient is identical, the side-effect profiles overlap heavily. Gastrointestinal effects dominate, nausea, diarrhoea, constipation, vomiting, particularly during dose escalation. Rarer but serious risks across all semaglutide products include pancreatitis and gallbladder disease. Semaglutide is not used in pregnancy. Our side effects covers recognition and management in depth, and suspected reactions can be reported to the HPRA.
The tablet-specific difference is administration: the empty-stomach rule and 30-minute wait are unique to oral semaglutide, and getting them wrong mostly costs effectiveness rather than safety, the medicine simply isn't absorbed.
How assessment works at WeightLossInjections.ie
Our process is deliberately simple and doctor-led. You complete a short online medical questionnaire, about three minutes, no video or phone call, for a flat €30 consultation fee, the same for first and repeat consultations, refunded in full if you're not suitable. An Irish-registered doctor reviews your history and decides whether treatment is clinically appropriate, and which product fits your situation. If a prescription is issued, it goes to your chosen Northern Ireland pharmacy partner for collection or delivery, with medication costs charged separately by the pharmacy. Not everyone is suitable, and a prescription is never guaranteed.
Frequently asked questions
Is the Wegovy pill just Ozempic in tablet form?
No. Same molecule, different product: the tablet is licensed for weight management at 25 mg; Ozempic is a diabetes injection at up to 2 mg weekly. The oral weight-management dose needed its own trial programme and its own licence.
Is Rybelsus a cheaper way to the same result?
No. Rybelsus tops out at 14 mg and is licensed for diabetes; the weight-management evidence belongs to the 25 mg Wegovy formulation. Taking a diabetes tablet for weight loss is off-label use at doses never shown to deliver weight-management results.
Why do you rank Ozempic content on a weight-loss site if you don't prescribe it? Because tens of thousands of Irish people search for it every month while actually looking for weight-management treatment, and accurate information beats letting the misunderstanding stand.
Can I get Ozempic through your service if I ask?
No Our doctors prescribe licensed weight-management medicines only, and never to people with diabetes.
References and further reading
- EMA — Wegovy, Ozempic and Rybelsus product information
- HPRA — Health Products Regulatory Authority
- HSE — Obesity and weight management
- WHO — Obesity and overweight
This article is for general educational purposes only and does not constitute medical advice. We do not prescribe Ozempic. Prescription-only medicines used in weight management are prescribed solely where an Irish-registered doctor determines it is clinically appropriate following an individual assessment. A prescription is not guaranteed. Always read the patient information leaflet and follow your prescriber's guidance.
